Erenumab-Aooe (Aimovig)

Trade Name : AIMOVIG

Amgen Inc

INJECTION

Strength 70 mg/mL

ERENUMAB

Delivery Process

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

We’ll Get in Touch

Once we review your request, we’ll send you an estimated price for the medicine within 2-5 days.

Confirmation and Payment

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Product information is meant for

Wholesalers Suppliers Exporters Doctors MOH Tender Supplies Hospitals Brand CROs Comparator Supplies Generic Cooperate Sourcing Individual Patients Indian Institutional Buyers

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India of Erenumab-Aooe (Aimovig) which is also known as AIMOVIG and Manufactured by Amgen Inc. It is available in strength of 70 mg/mL per ml. Read more

Erenumab-Aooe (Aimovig) is supplied for Tenders/ Emergency imports/ Un - licensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials. Click to know price. Read less

Packaging and Delivery

Validated Cold Chain Shipment

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Inquire directly from our website and get 5% off on any medicine!

About GNH

No data

No data

AIMOVIG is indicated for the preventive treatmentu00a0of migraineu00a0in adults.
AIMOVIG is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults. ()

No data

For subcutaneous use only (, )n
Recommended dosage is 70u00a0mg once monthly; some patients may benefit from a dosage of 140u00a0mg once monthly ()n
The needle shield within the white or orangeu00a0cap of theu00a0prefilled autoinjector and the gray needle cap of theu00a0prefilled syringe contain dry natural rubber (a derivative of latex), which may cause allergic reactions in individuals sensitive to latex ()n
Administer in the abdomen, thigh, or upper arm subcutaneously ()n
See Dosage and Administration for important administration instructions ()

AIMOVIG is a sterile, clear to opalescent, colorless to light yellow solution available as follows:

Injection: 70u00a0mg/mL solution in a single-dose prefilled SureClick autoinjector ()n
u00a0Injection: 140u00a0mg/mL in a single-dose prefilled SureClick autoinjectoru00a0()n
Injection: 70u00a0mg/mL solution in a single-dose prefilled syringe ()n
Injection: 140u00a0mg/mL solution in a single-dose prefilled syringe ()

AIMOVIG is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Reactions have included anaphylaxis and angioedema n n n
AIMOVIG is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients.u00a0()

No data

Hypersensitivity Reactions: If a serious hypersensitivity reaction occurs, discontinue administration of AIMOVIG and initiate appropriate therapy. Hypersensitivity reactions can occur within hours to more than one week after administration. ()n
Constipation with Serious Complications: Serious complications of constipation may occur. ()u00a0 n
Hypertension: New-onset or worsening of pre-existing hypertension may occur. ()u00a0

The following serious adverse reactions are described below and elsewhere in the labeling:
The most common adverse reactions in AIMOVIG clinical studies (occurring in at least 3% of treated patients and more often than placebo)u00a0are injection site reactions and constipation.u00a0()

No data

Erenumab-aooeu00a0is a human immunoglobulin G2 (IgG2) monoclonal antibody that has high affinity binding to the calcitonin gene-related peptide receptor. Erenumab-aooe is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. It is composed of 2 heavy chains, each containing 456 amino acids, and 2 light chains of the lambda subclass, each containing 216 amino acids, with an approximate molecular weight of 150u00a0kDa.
AIMOVIGu00a0(erenumab-aooe) injection is supplied as a sterile, preservative-free, clear to opalescent, colorless to light yellow solution for subcutaneous administration. Eachu00a01u00a0mL 70u00a0mgu00a0single-dose prefilledu00a0autoinjectoru00a0and 70u00a0mg single-dose prefilled glass syringe contains 70u00a0mg erenumab-aooe, acetate (1.5u00a0mg), polysorbateu00a080 (0.10u00a0mg), and sucrose (73u00a0mg). Each 1u00a0mL 140u00a0mg single-dose prefilledu00a0autoinjector and 140u00a0mg single-dose prefilled glass syringe contains 140u00a0mg erenumab-aooe, acetate (2.0u00a0mg), polysorbateu00a080 (0.10u00a0mg), and sucrose (65u00a0mg).u00a0Enclosed within the autoinjector is a single-dose, prefilled glass syringe.u00a0The solution of AIMOVIGu00a0has a pH of 5.2.

No data

Carcinogenesis
The carcinogenic potential of erenumab-aooeu00a0has not been assessed.
Mutagenesis
Genetic toxicology studies of erenumab-aooe have not been conducted.
Impairment of Fertility
Mating studies have not been conducted on erenumab-aooe. No histopathological changes in male or female reproductive organs were observed in monkeys administered erenumab-aooeu00a0(0, 25, or 150u00a0mg/kg) by subcutaneous injection twice weekly for up to 6u00a0months. Serum erenumab-aooe exposures (AUC) at the higher dose tested were more than 100 times that in humans at a dose of 140u00a0mg once monthly.

The efficacy of AIMOVIG was evaluated as a preventiveu00a0treatmentu00a0of episodic or chronic migraine in threeu00a0randomized, double-blind, placebo-controlled studies: twou00a0studies in patients with episodic migraineu00a0(4 to 14 migraine days per month) (Study 1 and Study 2) and one study in patients with chronic migraineu00a0(u2265u00a015 headache days per month with u2265u00a08 migraine days per month) (Study 3). Theu00a0studies enrolled patients with a history of migraine, with or without aura, according to the International Classification of Headache Disorders (ICHD-III) diagnostic criteria.
Episodic Migraine
Studyu00a01u00a0(NCT 02456740)u00a0was a randomized, multi-center, 6-month, placebo-controlled, double-blind study evaluating AIMOVIGu00a0for the preventiveu00a0treatmentu00a0of episodic migraine. A total of 955 patients with a history of episodic migraineu00a0were randomized to receive either AIMOVIG 70u00a0mg (Nu00a0=u00a0317),u00a0AIMOVIG 140u00a0mg (Nu00a0=u00a0319), or placebo (Nu00a0=u00a0319) by subcutaneous injection once monthly (QM) for 6u00a0months. Patients were allowed to use acute headache treatments including migraine-specific medications (i.e., triptans, ergotamine derivatives) and NSAIDsu00a0during the study.u00a0
The study excluded patients with medication overuse headache as well as patients with myocardial infarction, stroke, transient ischemic attacks, unstable angina, coronary artery bypass surgery, or other revascularization procedures within 12 months prior to screening.
The primary efficacyu00a0endpoint was the change from baseline in mean monthly migraine days over months 4 to 6. Secondary endpoints included the achievement of a u2265u00a050% reduction from baseline in mean monthly migraine days over months 4 to 6 (u201cu2265u00a050% MMD respondersu201d),u00a0the change from baseline in mean monthly acute migraine-specific medication days over months 4 to 6, and the change from baseline in mean Migraine Physical Function Impact Diary (MPFID) over months 4 to 6.u00a0The MPFID measures the impact of migraine on everyday activities (EA) and physical impairment (PI) using an electronic diary administered daily. Monthly MPFID scores are averaged over 28 days, including days with and without migraine; scores are scaled from 0 to 100. Higher scores indicate worse impact on EA and PI. Reductions from baseline in MPFID scores indicate improvement.
A total of 858 (90%) patients completed the 6-month double-blind study.u00a0Patients had a median age of 42u00a0years (range: 18u00a0tou00a065 years), 85% were female, and 89% were white.u00a0Three percent of patients were taking concomitant preventive treatments for migraine. The mean migraine frequency at baseline was approximately 8 migraine days per month and was similar across treatment groups.
AIMOVIG treatment demonstrated statistically significant improvements for key efficacy endpoints compared to placebo, as summarized in Tableu00a03.
Figure 2 shows theu00a0distribution of change from baseline in mean monthly migraine days over months 4 to 6 in bins of 2 days by treatment group. Au00a0treatment benefit over placebo for both doses of AIMOVIG is seen across a range of changes from baseline in monthly migraine days.
Compared to placebo, patients treated with AIMOVIG 70u00a0mg once monthly and 140u00a0mg once monthly showed greater reductions from baseline in mean monthly MPFID everyday activity scores averaged over months 4 to 6 [difference from placebo:u00a0u22122.2 for AIMOVIG 70u00a0mg and u22122.6 for AIMOVIG 140u00a0mg; -value
Studyu00a02 (NCT 02483585) was a randomized, multi-center, 3-month, placebo-controlled, double-blind study evaluating AIMOVIG for theu00a0preventive treatment of episodic migraine. A total of 577 patients with a history of episodic migraineu00a0were randomized to receive either AIMOVIG 70u00a0mg (Nu00a0=u00a0286) or placebo (Nu00a0=u00a0291) by subcutaneous injection once monthly for 3u00a0months. Patients were allowed to use acute headache treatments including migraine-specific medications (i.e., triptans, ergotamine derivatives) and NSAIDs during the study.u00a0
The study excluded patients with medication overuse headache as well as patients with myocardial infarction, stroke, transient ischemic attacks, unstable angina, coronary artery bypass surgery, or other revascularization procedures within 12 months prior to screening.
The primary efficacyu00a0endpoint was the change from baseline in monthly migraine days at month 3. Secondary endpoints included the achievement of a u2265u00a050% reduction from baseline in monthly migraine days (u201cu2265u00a050% MMD respondersu201d), the change from baseline in monthly acute migraine-specific medication days at month 3,u00a0and the proportion of patients with at least a 5-point score reduction from baseline in MPFID at month 3.u00a0
A total of 546 (95%) patients completed the 3-month double-blind study.u00a0Patients had a median age of 43u00a0years (range: 18u00a0tou00a065 years), 85% were female, and 90% were white.u00a0Six to seven percent of patients were taking concomitant preventive migraine treatment. The mean migraine frequency at baseline was approximately 8 migraine days per month and was similar between treatment groups.
AIMOVIG treatment demonstrated statistically significant improvements for key efficacy endpoints compared to placebo, as summarized in Tableu00a04.
Figure 4u00a0shows the distribution of change from baseline in monthly migraine days atu00a0month 3 in bins of 2 days by treatment group. A treatment benefit over placebo for AIMOVIG is seen across a range of changes from baseline in monthly migraine days.
The pre-specified analysis for the MPFID was based on at least a 5-point reduction within-patient responder definition. AIMOVIG 70u00a0mg once monthly was not significantly better than placebo for the proportion of responders for everyday activity [difference from placebo: 4.7%; odds ratiou00a0=u00a01.2; -valueu00a0=u00a00.26] and physical impairment [difference from placebo: 5.9%; odds ratiou00a0=u00a01.3; -valueu00a0=u00a00.13]. In an exploratory analysis of the changeu00a0from baseline in the mean MPFID scores at month 3, patients treated with AIMOVIG 70u00a0mg, as compared to placebo, showed nominally greater reductions of physical impairment scores [difference from placebo: -1.3; -valueu00a0=u00a00.021], but not of everyday activities scores [difference from placebo: -1.1; -valueu00a0=u00a00.061].
Chronic Migraine
Study 3 (NCT 02066415)u00a0was a randomized, multi-center, 3-month, placebo-controlled, double-blind study evaluating AIMOVIG as a preventiveu00a0treatment of chronic migraine. A total of 667 patients with a history of chronic migraine with or without aura were randomized to receive AIMOVIG 70u00a0mg (Nu00a0=u00a0191), AIMOVIG 140u00a0mg (Nu00a0=u00a0190), or placebo (Nu00a0=u00a0286) by subcutaneous injections once monthly for 3 months. Patients were allowed to use acute headache treatments including migraine-specific medications (i.e., triptans, ergotamine derivatives) and NSAIDs during the study.u00a0
The study excluded patients with medication overuse headache caused by opiate overuse and patients with concurrent use of migraine preventiveu00a0treatments. Patients with myocardial infarction, stroke, transient ischemic attacks, unstable angina, coronary artery bypass surgery, or other revascularization procedures within 12 months prior to screening were also excluded.
The primary efficacy endpoint was the change from baseline in monthly migraine days at month 3. Secondary endpoints included the achievement of a u2265u00a050% reduction from baseline in monthly migraine days (u201cu2265u00a050% MMD respondersu201d)u00a0and change from baseline in monthly acute migraine-specific medication days at month 3.u00a0
A total of 631 (95%) patients completed the 3-month double-blind study.u00a0Patients had a median age of 43u00a0years (range: 18u00a0tou00a066u00a0years), 83% were female, and 94% were white. The mean migraine frequency at baseline was approximately 18 migraine days per month and was similar across treatment groups.
AIMOVIG treatment demonstrated statistically significant improvements for key efficacy outcomes compared to placebo, as summarized in Tableu00a05.
Figure 6u00a0showsu00a0the distribution of change from baseline in monthly migraine days atu00a0month 3 in bins of 3 days by treatment group. A treatment benefit over placebo for both doses of AIMOVIG is seen across a range of changes from baseline in migraine days.

No data

Advise the patient to read the FDA-approved patient labeling ( and ).
Information on n- Pn- reparationn- and n- An- dministrationn- :
Provide guidance to patients and caregivers on proper subcutaneous administration technique, including aseptic technique, and how to use the single-dose prefilled autoinjector or single-dose prefilled syringeu00a0n n . Instruct patients and/or caregivers to read and follow the Instructions for Use each time they use AIMOVIG.
Advise latex-sensitive patients that the needle shield within the white or orangeu00a0cap of theu00a0AIMOVIG prefilled autoinjector and gray needle cap of theu00a0AIMOVIGu00a0prefilled syringe contain dry natural rubber (a derivative of latex) that may cause allergic reactions in individuals sensitive to latexu00a0n n n .
Hypersensitivity Reactionsn- :
Advise patients to seek immediate medical attention if they experience any symptoms of serious or severe hypersensitivity reactions n n .
Constipation with Serious Complications:
Advise patients that constipation with serious complications can occur with AIMOVIG and that they should contact their healthcare providers if they experience severe constipation n n .
Hypertension:
Advise patients that development of hypertension and worsening of pre-existing hypertension can occur with AIMOVIG and that they should contact their healthcare providers if they experience elevation in their blood pressure n n .
For more information, go to www.aimovig.com or call 1-800-77-AMGEN (1-800-772-6436).
AIMOVIG (erenumab-aooe)
Manufactured by:
Marketed by:
Patent:u00a0http://pat.amgen.com/aimovig/u00a9 2018-2020 Amgen Inc. All rights reserved.[part number] V4

No data

Important:
Important
Before you use n- AIMOVIGn- SureClick autoinjector, read this important information:
Storing your n- AIMOVIGn- SureClick autoinjector
Using your n- AIMOVIGn- SureClick autoinjector
Step 1: Prepare
AIMOVIG comes as a single-dose (1 time) prefilled autoinjector. Your healthcare provider will prescribe the dose that is best for you.
Before you inject, always check the label of your single-dose prefilled autoinjector to make sure you have the correct medicine and the correct dose of AIMOVIG.
A
Carefully lift the autoinjector straight up out of the carton.
Leave the autoinjector at room temperature for at least minutes before injecting.
u00a0u00a0u00a0u00a0u00a0
B
Make sure the medicine in the window is clear and colorless to slightly yellow.
In all cases, use a new autoinjector, and call 1-800-77-AMGEN (1-800-772-6436).
C
Wash your hands thoroughly with soap and water.
On a clean, well-lit work surface, place the:
D
Onlyn- usen- these injection sitesn- :
Clean your injection site with an alcohol wipe. Let your skin dry.
Step 2: Get ready
En- Do notn- fiven- minutes
It is normal to see a drop of liquid at the end of the needle or green safety guard.
F n- either n- or
Stretch method
Pinch method
Pinchu00a0the skin firmly between your thumb and fingers, creating an area about u00a0inches wide.
Important:
Step 3: Inject
G n- pn- utn- needle is inside
H n- push
Important:
In- press
Jn- pushing
Important:
Step 4: Finish
K
u00a0
Put the used AIMOVIGu00a0autoinjector and white cap in a FDA-cleared sharps disposal container right away after use. throw away (dispose of) the SureClick autoinjector in your household trash.
If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:
When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDAu2019s website at: http://www.fda.gov/safesharpsdisposal
Important:
L
If there is blood, press a cotton ball or gauze pad on your injection site. rub the injection site. Apply an adhesive bandage if needed.
Commonly asked questions
This Instructions for Use has been approved by the U.S. Food and Drugu00a0Administration.u00a0u00a0u00a0
AIMOVIG (erenumab-aooe)
Manufactured by:Amgen Inc.One Amgen Center DriveThousand Oaks, CA 91320-1799 USAU.S. License No. 1080
Marketed by:Amgen Inc. (Thousand Oaks, CA 91320), andNovartis Pharmaceuticals Corporation (East Hanover, NJ 07936)
u00a9 2018-2020 Amgen Inc. All rights reserved.u00a0
Revised: 02/2020 v3
u00a0

Important:
Important
Before you use AIMOVIG SureClick autoinjector, read this important information:
Storing your AIMOVIG SureClick autoinjector
Using your AIMOVIG SureClick autoinjector
Step 1: Prepare
AIMOVIG comes as a single-dose (1 time) prefilled autoinjector. Your healthcare provider will prescribe the dose that is best for you.
Before you inject, always check the label of your single-dose prefilled autoinjector to make sure you have the correct medicine and the correct dose of AIMOVIG.
A
Carefully lift the autoinjector straight up out of the carton.
Leave the autoinjector at room temperature for at least minutes before injecting.
Bn- u00a0u00a0
Make sure the medicine in the window is clear and colorless to slightly yellow.
In all cases, use a new autoinjector, and call 1-800-77-AMGEN (1-800-772-6436).
C n- u00a0
Wash your hands thoroughly with soap and water.
On a clean, well-lit work surface, place the:
D n- u00a0
Onlyn- usen- these injection sitesn- :
Clean your injection site with an alcohol wipe. Let your skin dry.
Step 2: Get ready
E n- Do notn- fiven- minutes
It is normal to see a drop of liquid at the end of the needle or yellow safety guard.
F n- eithern- or
Stretch method
Pinch method
Pinchu00a0the skin firmly between your thumb and fingers, creating an area about inches wide.
Important:
Step 3: Inject
G n- putn- needle is inside
H n- push
Important:
I n- press
J n- pushing
Important:
Step 4: Finish
K n- u00a0
Put the used AIMOVIG autoinjector and orange cap in a FDA-cleared sharps disposal container right away after use. throw away (dispose of) the SureClick autoinjector in your household trash.
If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:
When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDAu2019s website at: http://www.fda.gov/safesharpsdisposal
Important:
L n- u00a0
If there is blood, press a cotton ball or gauze pad on your injection site. rub the injection site. Apply an adhesive bandage if needed.
Commonly asked questions
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
AIMOVIG (erenumab-aooe)
Manufactured by:Amgen Inc.One Amgen Center DriveThousand Oaks, CA 91320-1799 USAU.S. License No. 1080
Marketed by:Amgen Inc. (Thousand Oaks, CA 91320), andNovartis Pharmaceuticals Corporation (East Hanover, NJ 07936)
u00a9 2019-2020 Amgen Inc. All rights reserved.u00a0
Revised: 02/2020 v2
Important:
Important
Before you use n- AIMOVIGn- prefilled syringe, read this important information:
Storing your n- AIMOVIGn- prefilled syringe
Using your n- AIMOVIGn- prefilled syringe
Step 1: Prepare
AIMOVIG comes as a single-dose (1 time) prefilled syringe. Your healthcare provider will prescribe the dose that is best for you.
Before you inject, always check the label of your single-dose prefilled syringe to make sure you have the correct medicine and the correct dose of AIMOVIG.
A
Grab the syringe barrel to remove the syringe from the tray.
For safety reasons:
Leave the syringe at room temperature for at least minutes before injecting.
Important: Always hold the prefilled syringe by the syringe barrel.
B
Always hold the syringe by the syringe barrel.
Make sure the medicine in the syringe is clear and colorless to slightly yellow.
In all cases, use a new syringe, and call 1-800-77-AMGEN (1-800-772-6436).
C
Wash your hands thoroughly with soap and water.
On a clean, well-lit work surface, place the:
D
Onlyn- usen- these injection sitesn- :
Clean your injection site with an alcohol wipe. Let your skin dry.
Step 2: Get ready
En- Do notn- fiven- minutes
It is normal to see a drop of liquid at the end of the needle.
Important:
F
u00a0u00a0u00a0n
Pinch skin firmly between your thumb and fingers, creating an area about u00a0inches wide.
Important:
Step 3: Inject
G
Do not
H
I
u00a0
Important:
Step 4: Finish
J n- u00a0
Put the used AIMOVIG syringe and gray needle cap in a FDA-cleared sharps disposal container right away after use. throw away (dispose of) the syringe in your household trash.
If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:
When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDAu2019s website at: http://www.fda.gov/safesharpsdisposal.
Important:
K
If there is blood, press a cotton ball or gauze pad on your injection site. rub the injection site. Apply an adhesive bandage if needed.
For more information, go to www.aimovig.com or call 1-800-77-AMGEN (1-800-772-6436).
AIMOVIG (erenumab-aooe)Manufactured by:Amgen Inc.One Amgen Center DriveThousand Oaks, CA 91320-1799 USAU.S. License No. 1080
Marketed by:Amgen Inc. (Thousand Oaks, CA 91320), andNovartis Pharmaceuticals Corporation (East Hanover, NJ 07936)
u00a9 2018-2020 Amgen Inc. All rights reserved.
Approved: 02/2020
[partnumber] v3

PRINCIPAL DISPLAY PANEL
1 x 70 mg/mL Prefilled Autoinjector
NDC 55513-841-01
Rx Only
AMGENn
NOVARTIS
aimovign
(erenumab-aooe)
Injection
70 mg/mL
70 mg/mL
Prefilled Autoinjector
For Subcutaneous Use Only
Store at 2u00b0C to 8u00b0C (36u00b0F to 46u00b0F) in original carton
to protect from light. Do Not Freeze. Do Not Shake.
Discard Any Unused Portion.
Keep out of the sight and reach of children.
For more information, go to Aimovig.com or
call 1-800-77-AMGEN (1-800-772-6436).
CAUTION, Consult
Accompanying Documents
Do Not Reuse
This Product Contains
Dry Natural Rubber.
No U.S. standard of potency

No data

PRINCIPAL DISPLAY PANEL
1 x 70 mg/mL Prefilled Syringe
NDC 55513-840-01
Rx Only
AMGENn
NOVARTIS
aimovign
(erenumab-aooe)
Injection
70 mg/mL
70 mg/mL
Single-dose Prefilled Syringe
For Subcutaneous Use Only
Store at 2u00b0C to 8u00b0C (36u00b0F to 46u00b0F) in original carton to protect
from light. Do Not Freeze. Do Not Shake. Discard Any Unused Portion.
Keep out of the sight and reach of children.
For more information, go to Aimovig.com or
call 1-800-77-AMGEN (1-800-772-6436).
CAUTION, Consult
Accompanying Documents
Do Not Reuse
This Product Contains
Dry Natural Rubber.
PRINCIPAL DISPLAY PANEL
1 x 140 mg/mL Prefilled Autoinjector
NDC 55513-843-01
Rx Only
AMGENn
NOVARTIS
aimovign
(erenumab-aooe)
Injection
140 mg/mL = 1 dose
140 mg/mL
Prefilled Autoinjector
For Subcutaneous Use Only
Store at 2u00b0C to 8u00b0C (36u00b0F to 46u00b0F) in original carton
to protect from light. Do Not Freeze. Do Not Shake.
Discard Any Unused Portion.
Keep out of the sight and reach of children.
For more information, go to Aimovig.com or
call 1-800-77-AMGEN (1-800-772-6436).
CAUTION, Consult
Accompanying Documents
Do Not Reuse
This Product Contains
Dry Natural Rubber.
No U.S. standard of potency
PRINCIPAL DISPLAY PANEL
1 x 140 mg/mL Prefilled Syringe
NDC 55513-842-01
Rx Only
AMGENn
NOVARTIS
aimovign
(erenumab-aooe)
Injection
140 mg/mL = 1 dose
140 mg/mL
Single-dose Prefilled Syringe
For Subcutaneous Use Only
Store at 2u00b0C to 8u00b0C (36u00b0F to 46u00b0F) in original carton to protect
from light. Do Not Freeze. Do Not Shake. Discard Any Unused Portion.
Keep out of the sight and reach of children.
For more information, go to Aimovig.com or
call 1-800-77-AMGEN (1-800-772-6436).
CAUTION, Consult
Accompanying Documents
Do Not Reuse
This Product Contains
Dry Natural Rubber.

Browse Our Services And Processes

Comparator Sourcing for Clinical Trials

GNH India brings over 10 years of experience in Comparator

Name Patient Supply

Today, the exact cause for many rare diseases remains unknown

Validated Cold Chain Shipment

With shifting of pharma industry from synthetic molecules to biologic

Clinical Trials Supply

STOP SOURCING..... START SMART SOURCING...... COME STRAIGHT TO THE SOURCE

Pharmaceutical Contract Manufacturing

GNH Provides Contract Manufacturing services for: Generic Medicines with following

Pricing

PRICING POLICY Terms of sales are typically prepaid, unless otherwise

Disclaimer

Please see the Legal Notice for detailed terms and disclaimers. The Legal Notice governs the use of this Website and by accessing and using this Website you agree to be bound by and accept the Legal Notice.

Browse from other international pharmaceuticals

General

64020 Products

GNH India Brings to over 64036 Product SKUs from India all at 1 place with easy access and global deliveries.

US NDC

71245 Products

GNH India Brings to over 71252 Product SKUs from India all at 1 place with easy access and global deliveries.

Canadian DIN

51046 Products

GNH India Brings to over 51047 Product SKUs from India all at 1 place with easy access and global deliveries.

Swiss Drugs

150 Products

GNH India Brings to over 150 Product SKUs from India all at 1 place with easy access and global deliveries.

NZ Drugs

13296 Products

GNH Brings to over 13298 Product SKUs from India all at 1 place with easy access and global deliveries.

FAQ

Check out our delivery process

Can’t find what
you’re looking for?

Get Price

Erenumab-Aooe (Aimovig)

Trade Name : AIMOVIG

INJECTION

Delivery Process

Product information is meant for

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

Packaging and Delivery

About GNH

Similar Products

Desogestrel And Ethinyl Estradiol (Emoquette)

Diphenoxylate Hydrochloride And Atropine Sulfate (Diphenoxylate Hydrochloride And Atropine Sulfate)

Fluoxetine Hydrochloride (Fluoxetine)

Metoprolol Succinate (Metoprolol Succinate)

Losartan Potassium (Losartan Potassium)

Browse Our Services And Processes

Disclaimer

Browse from other international pharmaceuticals

General

US NDC

Canadian DIN

Swiss Drugs

NZ Drugs

FAQ

Can’t find what
you’re looking for?

COMPANY

SERVICES

QUICK LINKS

CONTACT US

Erenumab-Aooe (Aimovig)

Trade Name : AIMOVIG

INJECTION

Delivery Process

Product information is meant for

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

Packaging and Delivery

About GNH

Similar Products

Desogestrel And Ethinyl Estradiol (Emoquette)

Diphenoxylate Hydrochloride And Atropine Sulfate (Diphenoxylate Hydrochloride And Atropine Sulfate)

Fluoxetine Hydrochloride (Fluoxetine)

Metoprolol Succinate (Metoprolol Succinate)

Losartan Potassium (Losartan Potassium)

Browse Our Services And Processes

Disclaimer

Browse from other international pharmaceuticals

General

US NDC

Canadian DIN

Swiss Drugs

NZ Drugs

FAQ

Can’t find what you’re looking for?

COMPANY

SERVICES

QUICK LINKS

CONTACT US

Can’t find what
you’re looking for?